Emyria Ltd (ASX:EMD) has enhanced its growth strategy with the appointment of Sixty Two Capital, a boutique corporate advisory, brokerage and investment group specialising in supporting the growth of emerging companies, as corporate advisor.
Sixty Two Capital will provide a range of corporate advisory services to the company in connection with its capital markets requirements, investor relations and the identification of additional, value-creating strategic opportunities.
Notably, Sixty Two had previously managed and cornerstoned two oversubscribed placements for Emyria in December 2020 and April 2021.
“Strong supporters”
Emyria managing director Dr Michael Winlo said: “The team at Sixty Two Capital have been strong supporters of Emyria ever since their first cornerstoned placement in December 2020.
“Sixty Two Capital has a track record of supporting high growth client companies over the long-term.
“We are delighted to have their support as Emyria advances our major programs in the new year.”
About Emyria
Emyria is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.
The company’s treatments target unmet needs and are focused on obtaining approval from major global regulators.
Furthermore, Emyria Data provides deep treatment insights and is, therefore, a source of unique IP, strategically designed drug development and personalised care programs.
“Potential to bring new treatments”
Sixty Two director Sufian Ahmad said: “Sixty Two Capital is delighted to assist Emyria in its next phase of growth as it seeks to develop registered medicines across its cannabinoid and psychedelic-assisted therapy portfolios.
“We believe that Emyria’s unique data-backed drug development platform has potential to bring new treatments to major patient populations globally, and in doing so, also generate significant returns for shareholders.”